Novo’s oral GLP-1 analog as add-on to insulin meets in Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported top-line data on Oct. 26 showing that oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 8 trial to treat Type II diabetes in patients treated with insulin.

On the trial's primary endpoint, once-daily 3, 7 and 14 mg doses of oral semaglutide plus insulin all significantly improved HbA1c from baseline to week 26 vs. placebo plus insulin, irrespective of treatment adherence or initiation of rescue medication...